R2. 최태웅 / Pf. 김진배. BACKGROUND  Ischemic stroke : leading causes of death and disability : cause remains unexplained after routine evaluation → Cryptogenic.

Slides:



Advertisements
Similar presentations
Screening and diagnosis of AF and stratifying stroke risk.
Advertisements

Preventing Strokes One at a Time Acute Interventions and Management 2009.
Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)
Automatic QRS Complex Detection Algorithm Designed for a Novel Electrocardiogram Recording Device Co-authors Kenneth Egstrup, OUH Svendborg Hospital Jens.
Atrial Fibrillation in Patients with Cryptogenic Stroke Gladstone DJ et al. N Engl J Med 2014; 370: Presented by Kris Huston | July 21, 2014.
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Syncope AM Report 6/25/10 Nicole Wilde. Syncope  Cause Not Obvious Neurally Mediated (vasovagal) 58% Cardiac Disease (arrhythmias) 23% Neurologic or.
Arrhythmias: The Good, the Bad and the Ugly
Improving Stroke Prevention in Patients With Atrial Fibrillation.
An Emergency Department Diagnostic Protocol For Patients With Transient Ischemic Attack: A Randomized Controlled Trial Michael A. Ross MD Scott Compton.
FERNE/EMRA The Management of ED TIA Patients: What is the optimal outpatient work-up, treatment and disposition?
The Long Term Multi-Center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) study To reviewers and moderators: These.
Secondary prevention after a TIA or ischemic stroke.
Randomized, double-blind, multicenter, controlled trial.
1 Statin treatment is associated with improved prognosis in patients with AF-related stroke G. Ntaios, V. Papavasileiou, K.Makaritsis, A.Karagiannaki,
PARTNER Objective To compare surgical aortic valve replacement (AVR) with transcatheter aortic valve replacement (TAVR) in high-risk patients with severe.
Terutroban versus aspirin in Patients with Cerebral Ischaemic Events (PREFORM): a Randomized, Double- blind Parallel-group Trial Daniel Wells Mercer University.
ARISTOTLE Objectives Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority.
Long-term mortality after acute stroke  Stroke is a leading cause of mortality: 6 million fatal events annually worldwide.  Mainly affects elderly, but.
Asklepios Klink St. Georg, Hamburg
VBWG In-hospital course of stroke patients with vs without AF Steger C et al. Eur Heart J. 2004;6:in press. More severe stroke on admission Lower Barthel.
SWEDMAF Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Carina Blomstrom-Lundqvist SWEDMAF Trial.
A-4 Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Pierre Jais Atrial Fibrillation Ablation vs. Antiarrhythmic Drugs Trial.
WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Rikki Weems, PGY III August 20, 2015
Gianluca Botto, FESC Presidente AIAC Associazione Italiana Aritmologia e Cardiostimolazione FA Sintomatica e Asintomatica Epidemiologia e Rischio Clinico.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. Benefit of Anticoagulation Unlikely in Patients With Atrial.
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D., Jyotsna Garg, M.S., Guohua Pan, Ph.D.,
Angela Aziz Donnelly April 5, 2016
Cost effectiveness of AF monitoring strategies in a post-stroke population LAUREN E. CIPRIANO JEFF HEALEY OMAR AKHTAR KAREN LEE LUCIANO A. SPOSATO APRIL.
Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D., Jyotsna Garg, M.S., Guohua Pan, Ph.D., Daniel E. Singer, M.D., Werner Hacke, M.D., Ph.D., Gunter Breithardt,
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015.
1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.
Journal of the American College of Cardiology Vol. 61, No. 4, 2013 Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation.
From: Incidence, Predictive Factors, and Prognostic Value of New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Implantation J Am Coll.
Cryptogenic Stroke and AF
Identifying patients with atrial fibrillation and "truly low" thromboembolic risk who are poorly characterized by CHA2DS2-VASc: Superior performance of.
Update on the Watchman Device CRT 2010 Washington, DC
Screening and diagnosis of AF and stratifying stroke risk
SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.
Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation (ISAR-TRIPLE Trial) - press conference - Katrin.
Management of atrial fibrillation. Patterns of Atrial Fibrillation.
C. ACC/AHA/ESC guidelines Role of anticoagulant therapy in AF
RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.
Monitoring Continuum ISSUE-3 Atrial Fibrillation Classification.
Setareh Omran, MD Vascular Neurology Fellow
Overall burden of AF associated with higher risk of thromboembolism and ischemic stroke An analysis of the KP-RHYTHM study, in patients with paroxysmal.
Disclosures. Evaluating Recent Clinical Trial Data in the Secondary Prevention of ACS.
Fibrillazione atriale
Oral Anticoagulants in AFa,b A Brief History.
Selecting NOACs for High-Risk Patients
Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.
Panelists. Secondary Prevention of Acute Ischemic Stroke: Can We Improve Outcomes?
Stroke and AF.
Assessing the Risk for Stroke in Patients With Atrial Fibrillation
Atrial Fibrillation.
Gregory Y.H. Lip, MD, Jonathan L. Halperin, MD, Hung-Fat Tse, MD, PhD 
Taking the "Cryptogenic" Out of Cryptogenic Stroke
Identifying High-Risk AF Patients
Study Background and Rationale Updated October 24, 2018
Long-term detection of atrial fibrillation with insertable cardiac monitors in a real-world cryptogenic stroke population  Paul D. Ziegler, John D. Rogers,
Ischemic Postconditioning
ACC 2003 Late Breaking Trials
Taking the "Cryptogenic" Out of Cryptogenic Stroke
What is “AF Burden”?. What is “AF Burden”? AF Burden and Stroke Risk ASSERT Study.
OPTIDUAL Trial design: Patients who received a drug-eluting stent and were event-free at 12 months were randomized to an additional 36 months of DAPT with.
Overall burden of AF associated with higher risk of thromboembolism and ischemic stroke An analysis of the KP-RHYTHM study, in patients with paroxysmal.
Figure 8. Stroke prevention strategy in patients with AF
NICE 2014 Check pulse in patients presenting with:
Presentation transcript:

R2. 최태웅 / Pf. 김진배

BACKGROUND  Ischemic stroke : leading causes of death and disability : cause remains unexplained after routine evaluation → Cryptogenic stroke  Atrial fibrillation : well-recognized cause of ischemic stroke → stroke risk reduced by anticoagulation : paroxysmal & asymptomatic nature (may not be detected with traditional monitoring techniques)

BACKGROUND  Strategies for detection of atrial fibrillation serial ECG, Holter monitoring monitoring with use of external event or loop recorders, long-term outpatient monitoring monitoring by means of insertable cardiac monitors (ICMs)  Current guidelines recommend → at least 24 hr of ECG monitoring after an ischemic stroke to rule out atrial fibrillation → most effective duration and type of monitoring not established

Material and Method  The Cryptogenic Stroke and Underlying AF(CRYSTAL AF) trial → parallel-group trial(randomized, controlled study) → comparing ICM vs conventional (24hr Holter, ECG, event recorder) f/u in patients with cryptogenic stroke or transient ischemic attack (TIA)  The primary end point time to first detection of A-fib at 6 months of f/u  Secondary end points time to first detection of A-fib at 12 months of f/u, recurrent stroke or TIA, and change in use of oral anticoagulant drugs

Material and Method

RESULTS

Detection of A-fib (6 months) 8.9% vs 1.4% (HR 6.4) Detection of A-fib (12 months) 12.4% vs 2.0% (HR 7.3)

RESULTS Detection of A-fib (36 months) 30% vs 3.0% (HR 8.8)

RESULTS

CONCLUSION  ECG monitoring with an ICM was superior to conventional follow- up for detecting atrial fibrillation after cryptogenic stroke  A-fib after cryptogenic stroke was most often asymptomatic and paroxysmal → unlikely to be detected by strategies based on symptom-driven monitoring or intermittent short-term recordings